NASHVILLE, Tenn. / Feb 20, 2025 / Business Wire / HCA Healthcare, Inc. (NYSE: HCA), is scheduled to present virtually at the following healthcare conferences:
March 4, 2025 at 1:50pm ET at TD Cowen’s 45th Annual Healthcare Conference.
March 11, 2025 at 1:30pm ET at Barclays’ 27th Annual Global Healthcare Conference.
March 19, 2025 at 2:15pm ET at KeyBanc’s 5th Annual Healthcare Forum.
March 20, 2025 at 10:00am ET at Oppenheimer’s 35th Annual Healthcare MedTech & Services Conference.
A link to the live audio webcast, where applicable, and copies of any related presentation materials will be made available at the Investor Relations section of the Company’s website, www.hcahealthcare.com.
Dates and times may be subject to change, please check the conference schedule or the Investor Relations section of the Company’s website for the latest information.
About HCA Healthcare
Nashville-based HCA Healthcare is one of the nation’s leading providers of healthcare services comprising 190 hospitals and approximately 2,400 ambulatory sites of care, including surgery centers, freestanding ERs, urgent care centers, and physician clinics, in 20 states and the United Kingdom.
All references to “Company” and “HCA” as used throughout this release refer to HCA Healthcare, Inc. and its affiliates.
| Last Trade: | US$376.59 |
| Daily Change: | -0.05 -0.01 |
| Daily Volume: | 937,092 |
| Market Cap: | US$95.390B |
April 25, 2025 February 18, 2025 | |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
